The benefit was seen as soon as 3 months. Investigators say there should be no delaying treatment for eligible patients.

Digital programs incorporating behavioral therapy led to solid reductions in body weight, and did so at lower drug doses.

Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.

This can be an important add-on to echocardiography in patients with a borderline need for intervention, researchers say.